Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNCaP human prostate cancer cell lines

Tousi, Marziyeh Shalchi; Sepehri, Houri; Khoee, Sepideh; Farimani, Mahdi Moridi; Delphi, Ladan; Mansourizadeh, Fariba

doi:10.1016/j.jpha.2020.04.002

Cited by 36 publications

(20 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the highly enhanced capability of double-receptor-targeting IONPs (LHRH-AE105-IONPs-PTX) to kill PC-3 cells (PCa cell line), it did not display noticeable toxicity to normal prostate epithelial cells (RC77N/E) at a concentration of 10 ng/mL, even the concentration doubled to 20 ng/mL [26]. Similarly, Eupatorin loaded Fe 3 O 4 @mPEG-b-PLGA nanoparticles demonstrated a significant reduction of growth of cancer cell lines e.g., DU-145 and LNCaP cell through apoptosis but found to be safe almost safe (displayed negligible toxicity) against HUVECs as normal cells [94]. Furthermore, ZnMn-IONPs significantly killed more than 90% PCa cells safely without noticeable toxicity to normal cells (non-malignant human embryonic kidney cells, HEK-293) [114].…”

Section: In Vitro Toxicitymentioning

confidence: 94%

“…Eupatorin loaded Fe 3 O 4 @mPEG-b-PLGA nanoparticles demonstrated a significant reduction of DU-145 and LNCaP cell growth through apoptosis by up-regulating Bax/Bcl2 ratio and the cleaved-caspase3 level with an entrapment efficacy of 90.99% ± 2.1%. In terms of safety, both free and IONP-conjugated eupatorin were found to be almost safe (displayed negligible toxicity) against HUVECs as normal cells [94].…”

Section: Phytochemical-based Therapymentioning

confidence: 99%

“…IONPs are conjugated with drugs, phytochemicals (natural anticancer agents), other polymers, and ligands that made them suitable for PCa treatment where many resistant drugs e.g., Docetaxel (DTX) became functional. IONP-based treatment approaches including photothermal therapy [92], radiotherapy [93], chemotherapy [26], bioactive compounds-based nanotherapy [94], and hyperthermia [60] can be used as an alternative to conventional therapy (Table 3 and Figure 3).…”

Section: Ionp-based Treatment Of Prostate Cancermentioning

confidence: 99%

“…Eupatorin (a flavonoid) has a range of phytomedical, tumor suppression, and apoptosis induction activity in multiple cancer cell lines including in the treatment of PCa. Tousi and his collegues developed poly(ethylene glycol) methyl ether-block-poly-lactide-co-glycolide (mPEG-b-PLGA) coated IONPs to act as a carrier for this phytochemical to increase its efficacy [94]. There was a sustainable release of eupatorin over 200 h with 100 µM (DU-145) and 75 µM (LNCaP) of IC 50 concentration.…”

Section: Phytochemical-based Therapymentioning

confidence: 99%

See 3 more Smart Citations

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignancy in men and the leading cause of death for men all over the world. Early diagnosis is the key to start treatment at an early stage of PCa and to reduce the death toll. Generally, PCa expresses characteristic morphologic features and serum biomarkers; however, early diagnosis is challenging due to its heterogeneity and long-term indolent phase in the early stage. Following positive diagnosis, PCa patients receive conventional treatments including surgery, radiation therapy, androgen deprivation therapy, focal therapy, and chemotherapy to enhance survival time and alleviate PCa-related complications. However, these treatment strategies have both short and long-term side effects, notably impotence, urinary incontinence, erectile dysfunctions, and recurrence of cancer. These limitations warrant the quest for novel PCa theranostic agents with robust diagnostic and therapeutic potentials to lessen the burden of PCa-related suffering. Iron oxide nanoparticles (IONPs) have recently drawn attention for their symmetrical usage in the diagnosis and treatment of several cancer types. Here, we performed a systematic search in four popular online databases (PubMed, Google Scholar, Scopus, and Web of Science) for the articles regarding PCa and IONPs. Published literature confirmed that the surface modification of IONPs with biopolymers and diagnostic biomarkers improved the early diagnosis of PCa, even in the metastatic stage with reliable accuracy and sensitivity. Furthermore, fine-tuning of IONPs with biopolymers, nucleic acids, anticancer drugs, and bioactive compounds can improve the therapeutic efficacy of these anticancer agents against PCa. This review covers the symmetrical use of IONPs in the diagnosis and treatment of PCa, investigates their biocompatibility, and examines their potential as PCa theranostic agents.

show abstract

Section: In Vitro Toxicitymentioning

confidence: 94%

Section: Phytochemical-based Therapymentioning

confidence: 99%

Section: Ionp-based Treatment Of Prostate Cancermentioning

confidence: 99%

Section: Phytochemical-based Therapymentioning

confidence: 99%

See 2 more Smart Citations

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The following supporting information can be downloaded at: , Table S1: Summary of plant-derived formulations that have been utilized in clinical trials against HPV, listed in chronological order, by chemical group association; Table S2: Summary of phytochemicals that have been screened against HPV listed in alphabetical order within the different chemical groups (↑: upregulation/induction/increase; ↓: downregulation/reduction/decrease). References [ 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 ] are cited in the Supplementary Materials.…”

mentioning

confidence: 99%

Natural Bioactives: Back to the Future in the Fight against Human Papillomavirus? A Narrative Review

Massa

Pagliarello

Paolini³

et al. 2022

JCM

View full text Add to dashboard Cite

Human papillomavirus (HPV) still represents an important threat to health worldwide. Better therapy in terms of further improvement of outcomes and attenuation of related side-effects is desirable. The pharmaceutical industry has always targeted natural substances—phytochemicals in particular—to identify lead compounds to be clinically validated and industrially produced as antiviral and anticancer drugs. In the field of HPV, numerous naturally occurring bioactives and dietary phytochemicals have been investigated as potentially valuable in vitro and in vivo. Interference with several pathways and improvement of the efficacy of chemotherapeutic agents have been demonstrated. Notably, some clinical trials have been conducted. Despite being endowed with general safety, these natural substances are in urgent need of further assessment to foresee their clinical exploitation. This review summarizes the basic research efforts conducted so far in the study of anti-HPV properties of bio-actives with insights into their mechanisms of action and highlights the variety of their natural origin in order to provide comprehensive mapping throughout the different sources. The clinical studies available are reported, as well, to highlight the need of uniformity and consistency of studies in the future to select those natural compounds that may be suited to clinical application.

show abstract

Noninvasive biosensing 3D scaffold to monitor degradation: The potential of fluorescent PCL and PLGA for tissue engineering

Balaburov,

Kamaraj,

Doyle

et al. 2023

J of Applied Polymer Sci

View full text Add to dashboard Cite

The nondestructive localization and traceability of polymers by fluorescent tagging has become a valuable tool for biomedical applications. Integration of fluorescent molecule to the pristine polymers could modify polymers' degradation rate which is still unpredictable from a scaffold application standpoint. The current study focused to understand the material perspective of fluorescently tagged biodegradable polymers such as polycaprolactone (PCL) and poly (d,l‐lactide‐co‐glycolide) (PLGA) with fluorescein amine isomer I (FITC). PCL‐FITC and PLGA‐FITC were characterized using FTIR for surface chemistry analysis and rheology for their mechanical properties. The grafted materials were utilized to form 3‐dimentional scaffolds, and their degradation was monitored under accelerated degradation conditions triggered by pH. It was found that PCL and PCL‐FITC had a very slow degradation rate, when compared to PLGA and PLGA‐FITC. Both the FITC tagged materials displayed a faster degradation rate compared to their respective pristine material. Biocompatibility of the FITC conjugated polymers was tested using human‐adipose derived stem cells (hADSCs) revealing that the sub products from the degradation of the polymers over 7 days did not negatively affect the cellular metabolic activity. This work highlights the significance of initial characterization of fluorescent modified polymers for future biomedical application.

show abstract

Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNCaP human prostate cancer cell lines

Cited by 36 publications

References 54 publications

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Natural Bioactives: Back to the Future in the Fight against Human Papillomavirus? A Narrative Review

Noninvasive biosensing 3D scaffold to monitor degradation: The potential of fluorescent PCL and PLGA for tissue engineering

Contact Info

Product

Resources

About